{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:01:08Z","timestamp":1793275268447,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.neuropharm.2013.05.028","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T02:32:08Z","timestamp":1370831528000},"page":"216-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys"],"prefix":"10.1016","volume":"73","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Morissette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baltazar","family":"Gomez-Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.05.028_bib1","series-title":"Geneva, Switzerland (Media Release)","author":"Addex Therapeutics","year":"2012"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/brain\/awr028","article-title":"Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias","volume":"134","author":"Ahmed","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1073\/pnas.1210984110","article-title":"Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography","volume":"110","author":"Akkus","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/syn.20400","article-title":"In\u00a0vitro and in\u00a0vivo characterization of [3H]CNS-5161\u2013a use-dependent ligand for the N-methyl-d-aspartate receptor in rat brain","volume":"61","author":"Biegon","year":"2007","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/mds.870110516","article-title":"Acute pharmacologic blockade of dyskinesias in Parkinson's disease","volume":"11","author":"Blanchet","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0149-7634(96)00038-3","article-title":"Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease","volume":"21","author":"Blanchet","year":"1997","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib12","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(10)70218-0","article-title":"Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap","volume":"9","author":"Calabresi","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","article-title":"Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias","volume":"61","author":"Calon","year":"2002","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","article-title":"Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment","volume":"26","author":"Calon","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1471-4159.2006.04124.x","article-title":"Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia","volume":"99","author":"Cenci","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib17","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib19","first-page":"CD003467","article-title":"Amantadine for dyskinesia in Parkinson's disease","author":"Crosby","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0028-3908(01)00082-X","article-title":"Differential modulation of the D1-like- and D2-like dopamine receptor-induced locomotor responses by group II metabotropic glutamate receptors in the rat nucleus accumbens","volume":"41","author":"David","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(03)01342-6","article-title":"Group I metabotropic glutamate receptors modulate glutamate and gamma-aminobutyric acid release in the periaqueductal grey of rats","volume":"462","author":"de Novellis","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1176\/appi.ajp.2011.09111607","article-title":"Reduced metabotropic glutamate receptor 5 density in major depression determined by [(11)C]ABP688 PET and postmortem study","volume":"168","author":"Deschwanden","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/jnr.20489","article-title":"Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease","volume":"80","author":"Domenici","year":"2005","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(24)23206-5","article-title":"Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-d-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease","volume":"57","author":"Dunah","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib30","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1097\/00001756-199412000-00045","article-title":"NMDA receptor blockade reverses motor response alterations induced by levodopa","volume":"5","author":"Engber","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib32","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00441-006-0266-5","article-title":"Metabotropic glutamate receptors","volume":"326","author":"Ferraguti","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.brainresrev.2007.11.007","article-title":"Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology","volume":"58","author":"Fuxe","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/ana.22423","article-title":"Therapies for dopaminergic-induced dyskinesias in Parkinson disease","volume":"69","author":"Gottwald","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1098-2396(19990601)32:3<153::AID-SYN2>3.0.CO;2-X","article-title":"Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys","volume":"32","author":"Goulet","year":"1999","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib36","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-DOPA-treated parkinsonian monkeys","volume":"17","author":"Gregoire","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pneurobio.2004.09.005","article-title":"Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases","volume":"74","author":"Gubellini","year":"2004","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.biopsych.2012.07.030","article-title":"Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep","volume":"73","author":"Hefti","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib41","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1523\/JNEUROSCI.5140-05.2006","article-title":"Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism","volume":"26","author":"Heimer","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.bmc.2006.10.038","article-title":"ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: identification, in\u00a0vitro pharmacology, pharmacokinetic and biodistribution studies","volume":"15","author":"Hintermann","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2013.05.028_bib43","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson's disease and l-DOPA induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejphar.2006.06.076","article-title":"Changes in mGlu5 receptor\u00a0expression in the basal ganglia of reserpinised rats","volume":"545","author":"Ismayilova","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib46","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-009-1600-x","article-title":"Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats","volume":"206","author":"Jimenez","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1471-4159.1996.67020608.x","article-title":"Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits","volume":"67","author":"Kendrick","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","article-title":"Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia","volume":"34","author":"Klockgether","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib50","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.54.8.1589","article-title":"AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys","volume":"54","author":"Konitsiotis","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0922-4106(94)90058-2","article-title":"Ligand affinities at recombinant N-methyl-d-aspartate receptors depend on subunit composition","volume":"268","author":"Laurie","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib53","doi-asserted-by":"crossref","first-page":"11888","DOI":"10.1073\/pnas.0502710102","article-title":"The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies","volume":"102","author":"Levesque","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib54","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on l-DOPA-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(97)00051-3","article-title":"Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites","volume":"13","author":"Lujan","year":"1997","journal-title":"J.\u00a0Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1098-2396(20000615)36:4<267::AID-SYN3>3.0.CO;2-Y","article-title":"Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats","volume":"36","author":"Marin","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib58","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/0006-8993(96)00693-2","article-title":"MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats","volume":"736","author":"Marin","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00726-001-0127-1","article-title":"Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia","volume":"23","author":"Marino","year":"2002","journal-title":"Amino Acids"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","article-title":"The \u2018magic\u2019 of l-DOPA: why is it the gold standard Parkinson's disease therapy?","volume":"26","author":"Mercuri","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0028-3908(02)00090-4","article-title":"Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract","volume":"43","author":"Messenger","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib67","article-title":"Modeling dyskinesia in animal models of Parkinson disease","author":"Morin","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib68","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1073\/pnas.0500914102","article-title":"Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice","volume":"102","author":"Morishima","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopa-induced dyskinesias by a selective NR1A\/2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib70","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1523\/JNEUROSCI.2582-06.2006","article-title":"Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia","volume":"26","author":"Nadjar","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib71","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib72","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","article-title":"Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias","volume":"38","author":"Ouattara","year":"2009","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib73","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","article-title":"Effect of l-DOPA on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys","volume":"113","author":"Ouattara","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib74","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib75","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(95)00924-3","article-title":"Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade","volume":"701","author":"Papa","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib77","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1523\/JNEUROSCI.23-20-07659.2003","article-title":"Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents","volume":"23","author":"Paquet","year":"2003","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib78","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.1074\/jbc.M705661200","article-title":"Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors","volume":"283","author":"Perroy","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib79","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/brain\/awf269","article-title":"Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment","volume":"125","author":"Picconi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0306-4522(01)00297-4","article-title":"Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons","volume":"106","author":"Pisani","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib81","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/mds.870130520","article-title":"New use for an old drug: amantadine benefits levodopa-induced dyskinesia","volume":"13","author":"Rajput","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib82","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0306-4522(98)00370-4","article-title":"Dopamine D1 receptor modulation of glutamate receptor messenger RNA levels in the neocortex and neostriatum of unilaterally 6-hydroxydopamine-lesioned rats","volume":"89","author":"Rodriguez-Puertas","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0163-7258(00)00098-X","article-title":"Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders","volume":"88","author":"Rouse","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib84","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s007020070019","article-title":"Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease","volume":"107","author":"Ruzicka","year":"2000","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib85","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib87","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.neuropharm.2007.08.009","article-title":"Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of l-DOPA-induced dyskinesias","volume":"54","author":"Samadi","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib88","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/NEN.0b013e31819cabe4","article-title":"Metabotropic glutamate receptor II in the brains of Parkinsonian patients","volume":"68","author":"Samadi","year":"2009","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0072-9752(07)83002-8","article-title":"Functional neurochemistry of the basal ganglia","volume":"83","author":"Samadi","year":"2007","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib92","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-138-8-200304150-00013","article-title":"Update on Parkinson disease","volume":"138","author":"Siderowf","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2013.05.028_bib94","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib95","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cne.902220208","article-title":"A\u00a0stereotaxic atlas of the brain of the cynomolgus monkey (Macaca fascicularis)","volume":"222","author":"Szabo","year":"1984","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<5::AID-CNE2>3.0.CO;2-6","article-title":"Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2\/3 in the rat basal ganglia","volume":"390","author":"Testa","year":"1998","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib97","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1523\/JNEUROSCI.14-05-03005.1994","article-title":"Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat","volume":"14","author":"Testa","year":"1994","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib98","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1212\/WNL.51.1.203","article-title":"Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease","volume":"51","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib99","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2013.05.028_bib100","first-page":"9","article-title":"Functional neuroanatomy of the basal ganglia in Parkinson's disease","volume":"91","author":"Wichmann","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib101","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11596-009-0204-3","article-title":"Quantitative autoradiographic study on receptor regulation in the basal ganglia in rat model of levodopa-induced motor complications","volume":"29","author":"Xu","year":"2009","journal-title":"J.\u00a0Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.neuropharm.2013.05.028_bib102","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.neuroscience.2009.07.060","article-title":"Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"163","author":"Yamamoto","year":"2009","journal-title":"Neuroscience"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813002426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T12:00:33Z","timestamp":1746014433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813002426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":102,"alternative-id":["S0028390813002426"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.028","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}